Biosimilar Ranibizumab

About Organon (2)

Organon is a mission-driven global healthcare company established in 2021 as a spin-off from Merck & Co., with a dedicated focus on women's health. Its strategy is built on three core pillars: advancing a portfolio of women's health therapies, expanding access through biosimilars, and maximizing the value of a broad range of established medicines. The company has achieved immediate global scale, operating in over 140 markets, and is recognized for its strong corporate governance and commitment to addressing healthcare inequities.

About Paras Biopharmaceuticals Finland

Paras Biopharmaceuticals is a private, pre-revenue Finnish biotech focused on developing biosimilars and proprietary microbial expression technologies. The company operates a three-pronged business model encompassing a microbial biologics CDMO service, biosimilar technology development partnerships, and the sale of recombinant bioprocess enzymes. With a suite of proprietary platforms like Diabrid®, NobleCleav®, and Biomultifold®, Paras aims to enable cost-effective, high-yield production of complex therapeutic proteins and peptides. It is actively seeking partners to advance its pipeline of biosimilar candidates for osteoporosis, rheumatoid arthritis, and other conditions.

Therapeutic Areas

Other Ophthalmology (nAMD, DME, RVO) Drugs